AEON Biopharma Files 8-K with Financials
Ticker: AEON · Form: 8-K · Filed: May 20, 2025 · CIK: 1837607
Sentiment: neutral
Topics: 8-K, financial-reporting, regulatory-disclosure
TL;DR
AEON Biopharma dropped an 8-K, check the financials.
AI Summary
AEON Biopharma, Inc. filed an 8-K on May 20, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Priveterra Acquisition Corp., is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing provides an update on AEON Biopharma's regulatory disclosures and financial reporting, which is crucial for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This is a routine filing for financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- May 20, 2025 (date) — Date of report
- Irvine, CA (location) — Principal executive offices
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but the specific details of these statements are not provided in the excerpt.
When was AEON Biopharma, Inc. formerly known as Priveterra Acquisition Corp.?
The date of the name change from Priveterra Acquisition Corp. to AEON Biopharma, Inc. was December 22, 2020.
What is AEON Biopharma's principal executive office address?
AEON Biopharma's principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for AEON Biopharma, Inc.?
The Standard Industrial Classification (SIC) code for AEON Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding AEON Biopharma, Inc. (AEON).